

### Abstract

5 A vaccine for the treatment or prophylaxis of *C. difficile* associated disease comprises a *C. difficile* gene or a *C. difficile* peptide/polypeptide or a derivative or fragment or mutant or variant thereof which is immunogenic in humans. The gene encodes a *C. difficile* surface layer protein, SlpA or variant or homologue thereof. The peptide/polypeptide is a *C. difficile* surface layer protein, SlpA or variant or homologue thereof. The vaccine may comprise a chimeric nucleic acid sequence.

10

20160707 09:09:00